相关实验视频
Updated: Jul 23, 2025
05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.2K
丹申苏通过向细胞中的IKKβ介导炎症来稳定动脉样硬化易受损伤的斑块
Miao Zeng1, Xiaolu Zhang1, Nuan Lv1
1School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
概括
丹申苏 (SDSS) 通过向IKKβ和抑制NF-κB通路来稳定动脉样硬化斑块并减少炎症. 这一发现为治疗由斑块破裂引起的心血管事件提供了新的见解.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 动脉硬性斑块破裂导致血栓形成是心血管死亡的主要原因.
- 丹申苏 (SDSS) 在减少巨细胞炎症和早期斑块形成方面表现有前途.
- SDSS行动的确切目标和机制尚未完全阐明.
研究的目的:
- 研究SDSS在稳定易受动脉样硬化斑块方面的有效性.
- 阐明SDSS在抑制炎症和斑块进展中的作用机制.
- 在动脉样硬化背景下确定SDSS的分子标.
主要方法:
- 动脉样硬化在ApoE-/-小鼠中被研究,使用包括超声波,油红O,HE和马森染色在内的技术.
- 通过蛋白质微阵列,网络药理学和分子对接,IKKβ被确定为目标.
- 使用ELISA,RT-qPCR,西部斑点和免疫光检测来评估炎症标志物和NF-κB通路激活.
主要成果:
- SDSS减少了大动脉斑块的形成和面积,稳定了小鼠的脆弱斑块.
- 证实IKKβ是SDSS的主要结合性目标.
- 在体内和体外,SDSS通过准IKKβ来抑制NF-κB通路.
- 与IKKβ抑制剂联合使用增强了SDSS效应.
结论:
- SDSS有效地稳定了脆弱的动脉样硬化斑块.
- SDSS通过抑制NF-κB通路来抑制炎症反应.
- 向IKKβ是SDSS在动脉样硬化中发挥治疗作用的关键机制.
相关概念视频
01:38Inflammation
53.9K
Overview
53.9K
01:30Atherosclerosis I: Introduction
11
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
11
01:26Atherosclerosis III: Management
13
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13
01:26Coronary Artery Disease II: Pathophysiology
13
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
13
01:30Peripheral Artery Disease I: Introduction
10
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
10
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K